Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome
Tenzin Gayden,Fernando E Sepulveda,Dong-Anh Khuong-Quang,Jonathan Pratt,Elvis T Valera,Alexandrine Garrigue,Susan Kelso,Frank Sicheri,Leonie G Mikael,Nancy Hamel,Andrea Bajic,Rola Dali,Shriya Deshmukh,Dzana Dervovic,Daniel Schramek,Frédéric Guerin,Mikko Taipale,Hamid Nikbakht,Jacek Majewski,Despina Moshous,Janie Charlebois,Sharon Abish,Christine Bole-Feysot,Patrick Nitschke,Brigitte Bader-Meunier,David Mitchell,Catherine Thieblemont,Maxime Battistella,Simon Gravel,Van-Hung Nguyen,Rachel Conyers,Jean-Sebastien Diana,Chris McCormack,H Miles Prince,Marianne Besnard,Stephane Blanche,Paul G Ekert,Sylvie Fraitag,William D Foulkes,Alain Fischer,Bénédicte Neven,David Michonneau,Geneviève de Saint Basile,Nada Jabado
DOI: https://doi.org/10.1038/s41588-018-0251-4
Abstract:Subcutaneous panniculitis-like T cell lymphoma (SPTCL), a non-Hodgkin lymphoma, can be associated with hemophagocytic lymphohistiocytosis (HLH), a life-threatening immune activation that adversely affects survival1,2. T cell immunoglobulin mucin 3 (TIM-3) is a modulator of immune responses expressed on subgroups of T and innate immune cells. We identify in ~60% of SPTCL cases germline, loss-of-function, missense variants altering highly conserved residues of TIM-3, c.245A>G (p.Tyr82Cys) and c.291A>G (p.Ile97Met), each with specific geographic distribution. The variant encoding p.Tyr82Cys TIM-3 occurs on a potential founder chromosome in patients with East Asian and Polynesian ancestry, while p.Ile97Met TIM-3 occurs in patients with European ancestry. Both variants induce protein misfolding and abrogate TIM-3's plasma membrane expression, leading to persistent immune activation and increased production of inflammatory cytokines, including tumor necrosis factor-α and interleukin-1β, promoting HLH and SPTCL. Our findings highlight HLH-SPTCL as a new genetic entity and identify mutations causing TIM-3 alterations as a causative genetic defect in SPTCL. While HLH-SPTCL patients with mutant TIM-3 benefit from immunomodulation, therapeutic repression of the TIM-3 checkpoint may have adverse consequences.